PTC Therapeutics, Inc. (NASDAQ: PTCT) reported insider activity this week as Mark Elliott Boulding, the company’s executive vice president and chief legal officer, sold a total of 5,894 shares of common stock across transactions executed on February 17 and 18, 2026. The aggregate proceeds from those sales amounted to $408,612.
Transaction details show that on February 17 Boulding disposed of 2,813 shares at a weighted average price of $69.29 per share, producing $194,914 in proceeds. The per-share prices on that day ranged between $68.84 and $69.80. In a separate, smaller sale that same day, Boulding sold 2 shares at $70.13 each, totaling $140. The following day, February 18, he sold an additional 3,081 shares at $69.36 per share, resulting in proceeds of $213,698.
Alongside those sales, Boulding exercised stock options to acquire 2,813 shares of PTC Therapeutics common stock at an exercise price of $25.69 per share. The exercise carried a total cost of $72,265. The trading and option activity were executed under a pre-arranged Rule 10b5-1 trading plan that the executive adopted on December 4, 2024.
These insider actions coincide with a series of corporate updates from PTC Therapeutics. The company reported that its PKU treatment, Sephience, generated $92.5 million in revenue during the fourth quarter, contributing to PTC’s total product and royalty revenue of approximately $823.4 million for 2025. That full-year figure exceeded the company’s prior guidance.
Separately, PTC announced regulatory progress in Asia: the Japanese Ministry of Health, Labor and Welfare approved Sephience, marking the company’s first product approval in Japan. In contrast to that regulatory win, PTC recently elected to withdraw its New Drug Application for Translarna after receiving feedback from the U.S. Food and Drug Administration indicating that the available data was unlikely to satisfy the agency’s threshold for approval.
On the analyst front, Barclays initiated coverage of PTC Therapeutics with an Overweight rating and highlighted the potential for the company’s PKU treatment to produce more than $2 billion in peak sales. Goldman Sachs adjusted its view on valuation by increasing its price target to $55 from $50, while retaining a Sell rating and pointing to the company’s progress on drug development platforms.
Investors seeking detailed analysis of insider transactions and additional research on PTC Therapeutics can consult InvestingPro, which offers pro research reports and expanded coverage for U.S. equities.
The disclosures around the February insider sales, the option exercise, the 10b5-1 plan and the company’s recent operational and regulatory developments provide a compact view of concurrent corporate and insider activity at PTC Therapeutics as it advances Sephience globally and reassesses other development programs.